Eyal Reinstein

Eyal serves as the Chief Medical Officer and joined Variantyx in December 2019 as a medical director reviewing, advising, and approving clinical cases. Eyal earned his PhD in biochemistry and MD in internal medicine, both from the Technion-Israel Institute of Technology. He completed his clinical genetics fellowship at the UCLA Medical Genetics Program. During his career, he has authored over 50 scientific papers delineating novel genetic disorders and phenotypes including heritable connective tissue disorders, cardiac and eye abnormalities, and intellectual disability syndromes. Prior to joining Variantyx, he served as a clinical geneticist in multiple academic medical centers, was the Director of the Department of Medical Genetics at Meir Medical Center in Israel, and an Associate Professor of Internal Medicine at Tel-Aviv University. From 2016-2021, he served as a member of both the Helsinki Committee of the Israel Ministry of Health and the Meir Medical Center. He is a diplomate of the American Board of Medical Genetics and Genomics.